Dr. Rachel Tate
Tweet
I love a good graphic. Check out @DrLauraCoates’ review of the impact of MDA in PSAID scores in PsA. #RNL2023 @RheumNow https://t.co/iQYuLQobXL
All News
Eric Dein
Tweet
Treat to target in PSA: What's difference in our outcome scores?
DAPSA: includes CRP
MDA: includes enthesitis, skin, function
Both metrics include Tender/Swollen jt counts, and pt pain/global
Presented by @DrLauraCoates at #RNL2023
@RheumNow https://t.co/7i5m70HGiz
Robert B Chao, MD
Tweet
Dr. Laura Coates presents - Is remission in PsA attainable?
systematic review: 12-43% achieved very low disease activity or remission
#RNL2023 @RheumNow https://t.co/flfpzc7B4p
Nouf Al hemmadi
Tweet
Triamcinolone joint injection, Dr.Conaghan #RNL2023 @RheumNow
Extended half life steroids injections are better?!:
1- better for sugar control.
2-longer effect. https://t.co/4T8frPJOXG
Eric Dein
Tweet
#RNL2023 @RheumNow
@DrLauraCoates: patients & physicians do not agree on what is remission in PsA
Patients global scores: largely driven by pain and fatigue, not on joint counts
Remission in PsA allows for disease control on Rx- not just drug-free remission, often not sustained https://t.co/Hr2uuWDAfr
Dr. John Cush
Tweet
Higher Rehospitalization Rates in Younger SLE Patients
A Medicare study shows that young adults with SLE exhibit very high 30-day rehospitalization rates (36%) that are significantly higher than older SLE patients and age matched non-SLE patients.
https://t.co/17Lbcw8TdC https://t.co/L6CwRCd1aS
Nouf Al hemmadi
Tweet
Can we prevent RA, Kevin Deane #RNL2023 @RheumNow. https://t.co/EtUEs3MyCN
Dr Gurdeep Dulay
Tweet
Upto 30% risk of #RA within 5 yrs if anti-CCP positive
#RNL23 https://t.co/E5wun837ud
Eric Dein
Tweet
Conaghan: "Most promising study in OA" at #RNL2023
NGF inhibitor to OA had benefit, but very poorly tolerated - could this be a future tolerated?
Can there be sustained response.
Conaghan: "In meantime, keep everybody strong" as primary treatment! 💪
@RheumNow https://t.co/eBMEPBG9wn
Nouf Al hemmadi
Tweet
Stop RA trail:
Plaquenil didn’t prevent RA in patient with pre clinical RA. Kevin Deane #RNL2023 @RheumNow https://t.co/2Y5am2YEsQ
Eric Dein
Tweet
Conaghan shares unpublished data from PROMOTE study at #RNL2023
Early data shows MTX benefits pain in patients w/ OA, particularly more metabolically active.
Looking forward to more data on this - though many many many DMARD trials thus far have been disappointing in OA
@RheumNow https://t.co/Ieagp8mq31
Nouf Al hemmadi
Tweet
30% rule!
Risk of RA development in Pre clinical RA patient in the next 3 to 5 years .
Kevin Deane #RNL2023 @RheumNow https://t.co/J6Polz70im
Eric Dein
Tweet
Dr Philip Conaghan at #RNL2023
X-rays are misleading in OA
OA is a CLINICAL disease
Radiographs do not help in diagnosis or monitoring
@RheumNow https://t.co/ZrAfPN02qi
Eric Dein
Tweet
#RNL2023 @RheumNow
There are a lot of RA Rx on market now - do we need more?
Dr. Brenner: YES
Stromal targets like LIF/LIFR, Notch3, cadherin-11 offer upstream benefits for our difficult to treat RA patients that don't respond to tradition cs/bDMARDs https://t.co/zJRRisGW9i
Eric Dein
Tweet
@RheumNow Live #RNL2023
Stanley Cohen, MD:
Use of JAK inhibitor in patients with known ASCVD: Number needed to harm 16
ASCVD is biggest risk factor for MACE events with JAKi https://t.co/gXNUOO8seG
Eric Dein
Tweet
Dr Brenner at #RNL2023
Excellent description on how fibroblasts are major producers of IL-6 producers
Clinically presents a target for blocking the fibroblasts, upstream the inflammatory cascade in RA
@RheumNow https://t.co/TserFZtvhV
Robert B Chao, MD
Tweet
JAKinib safety takeaways
- avoid in older population > 65 yo, malignancy, CV risk, VTE risk
- appropriate in younger pts without VTE/CVD risk factors
#RNL2023 @RheumNow https://t.co/5i1bRqqr7g
Eric Dein
Tweet
@RheumNow Live 2023 Starts Tomorrow!
Or does it start earlier?
Love that there is a pre-learn and pre-test to set the stage for #RNL2023
Excited for this talk by @anisha_dua on assessment for GCA/PMR
#RheumTwitter https://t.co/VcawlnaPFf
Dr. John Cush
Tweet
Faith and Miracle Larry
This week on the podcast, Dr. Jack Cush recalls what life was like early on during COVID, from March to June of 2020.
https://t.co/SfidfBF1En https://t.co/Jnv6moxYwQ
Eric Dein
Tweet
#RNL2023 @RheumNow
Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Occasional cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/AZDKShOPbU
